MitoRx Therapeutics
Oxford, United Kingdom · Biotechnology, Health Care, Therapeutics · 13 employees
MitoRx Therapeutics is a pre-clinical stage rare disease biotech company aiming to become the leading global developer of medicines arresting the progression of degenerative diseases driven by mitochondrial dysfunction, with a focus on neuromuscular disease, metabolic disease and neurodegenerative disease.
Funding history
- Series PRE-SERIES A — $5.5M — Nov 2025
- Series Seed — Undisclosed — Apr 2022
Recent signals
- Jun 09, 2026: MitoRx Appoints Alison Strutt as Chief Financial Officer and László Tankó as Chief Marketing Officer
- Nov 17, 2025: Raised $5.5M in Series PRE-SERIES A
- Jan 09, 2025: MitoRx Therapeutics Appoints Dr. Lubor Gaal as Chief Business Officer and Stacey Massey as Finance Director
- Apr 25, 2022: Raised funding in Series Seed
See plans & pricing → Track MitoRx Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.